Paladin Labs, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paladin Labs, Inc.
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Allon Therapeutics, Inc.
- Ativa Pharma S.A,
- Labopharm Inc.
- ViRexx Medical Corp.
- Triton Pharma Inc.